Charles Schwab’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.7M | Buy |
1,956,775
+645,477
| +49% | +$1.26M | ﹤0.01% | 2513 |
|
|
2026
Q1 | $2.05M | Buy |
1,311,298
+256,175
| +24% | +$373K | ﹤0.01% | 2715 |
|
|
2025
Q4 | $1.21M | Sell |
1,055,123
-89,509
| -8% | -$123K | ﹤0.01% | 2860 |
|
|
2025
Q3 | $1.55M | Buy |
1,144,632
+261,405
| +30% | +$297K | ﹤0.01% | 2814 |
|
|
2025
Q2 | $835K | Sell |
883,227
-267,544
| -23% | -$173K | ﹤0.01% | 2956 |
|
|
2025
Q1 | $530K | Sell |
1,150,771
-40,320
| -3% | -$25.4K | ﹤0.01% | 3062 |
|
|
2024
Q4 | $880K | Sell |
1,191,091
-226,204
| -16% | -$273K | ﹤0.01% | 2958 |
|
|
2024
Q3 | $2.23M | Buy |
1,417,295
+58,147
| +4% | +$104K | ﹤0.01% | 2678 |
|
|
2024
Q2 | $2.28M | Buy |
1,359,148
+478,025
| +54% | +$857K | ﹤0.01% | 2667 |
|
|
2024
Q1 | $2.11M | Buy |
881,123
+16,948
| +2% | +$36.4K | ﹤0.01% | 2576 |
|
|
2023
Q4 | $1.32M | Buy |
864,175
+12,254
| +1% | +$14.6K | ﹤0.01% | 2747 |
|
|
2023
Q3 | $929K | Buy |
851,921
+139,546
| +20% | +$245K | ﹤0.01% | 2825 |
|
|
2023
Q2 | $1.63M | Buy |
712,375
+23,764
| +3% | +$63.1K | ﹤0.01% | 2613 |
|
|
2023
Q1 | $1.67M | Sell |
688,611
-7,329
| -1% | -$16.8K | ﹤0.01% | 2572 |
|
|
2022
Q4 | $1.33M | Buy |
695,940
+33,462
| +5% | +$71.2K | ﹤0.01% | 2685 |
|
|
2022
Q3 | $1.59M | Buy |
662,478
+227,914
| +52% | +$631K | ﹤0.01% | 2647 |
|
|
2022
Q2 | $809K | Sell |
434,564
-66,564
| -13% | -$127K | ﹤0.01% | 2875 |
|
|
2022
Q1 | $1.05M | Buy |
501,128
+12,710
| +3% | +$35.2K | ﹤0.01% | 2831 |
|
|
2021
Q4 | $1.93M | Buy |
488,418
+12,624
| +3% | +$61.3K | ﹤0.01% | 2715 |
|
|
2021
Q3 | $2.29M | Buy |
475,794
+6,090
| +1% | +$25K | ﹤0.01% | 2667 |
|
|
2021
Q2 | $2.16M | Buy |
469,704
+46,478
| +11% | +$224K | ﹤0.01% | 2694 |
|
|
2021
Q1 | $2.48M | Buy |
423,226
+89,440
| +27% | +$619K | ﹤0.01% | 2602 |
|
|
2020
Q4 | $1.14M | Buy |
333,786
+38,657
| +13% | +$73.7K | ﹤0.01% | 2731 |
|
|
2020
Q3 | $425K | Buy |
295,129
+11,235
| +4% | +$20K | ﹤0.01% | 2919 |
|
|
2020
Q2 | $567K | Buy |
283,894
+17,201
| +6% | +$33.7K | ﹤0.01% | 2781 |
|
|
2020
Q1 | $521K | Buy |
266,693
+3,843
| +1% | +$11.4K | ﹤0.01% | 2701 |
|
|
2019
Q4 | $1.09M | Buy |
262,850
+31,439
| +14% | +$121K | ﹤0.01% | 2567 |
|
|
2019
Q3 | $697K | Sell |
231,411
-37,503
| -14% | -$116K | ﹤0.01% | 2674 |
|
|
2019
Q2 | $1.69M | Buy |
268,914
+3,684
| +1% | +$22.1K | ﹤0.01% | 2424 |
|
|
2019
Q1 | $1.48M | Buy |
265,230
+5,729
| +2% | +$34.8K | ﹤0.01% | 2450 |
|
|
2018
Q4 | $1.72M | Sell |
259,501
-6,744
| -3% | -$54.6K | ﹤0.01% | 2385 |
|
|
2018
Q3 | $2.84M | Buy |
266,245
+25,184
| +10% | +$289K | ﹤0.01% | 2313 |
|
|
2018
Q2 | $2.89M | Buy |
241,061
+14,426
| +6% | +$148K | ﹤0.01% | 2255 |
|
|
2018
Q1 | $1.94M | Buy |
226,635
+7,078
| +3% | +$65.5K | ﹤0.01% | 2345 |
|
|
2017
Q4 | $2.17M | Buy |
219,557
+15,428
| +8% | +$160K | ﹤0.01% | 2278 |
|
|
2017
Q3 | $2.51M | Buy |
204,129
+10,811
| +6% | +$160K | ﹤0.01% | 2212 |
|
|
2017
Q2 | $3.18M | Buy |
193,318
+1,633
| +0.9% | +$25.3K | ﹤0.01% | 2041 |
|
|
2017
Q1 | $2.75M | Sell |
191,685
-122,226
| -39% | -$1.81M | ﹤0.01% | 2069 |
|
|
2016
Q4 | $4.34M | Sell |
313,911
-1,234
| -0.4% | -$19.8K | ﹤0.01% | 1821 |
|
|
2016
Q3 | $5.7M | Buy |
315,145
+9,942
| +3% | +$160K | 0.01% | 1558 |
|
|
2016
Q2 | $4.38M | Buy |
305,203
+152,735
| +100% | +$2.07M | 0.01% | 1650 |
|
|
2016
Q1 | $1.82M | Buy |
152,468
+3,375
| +2% | +$35.4K | ﹤0.01% | 2097 |
|
|
2015
Q4 | $1.99M | Buy |
149,093
+4,338
| +3% | +$53.3K | ﹤0.01% | 2084 |
|
|
2015
Q3 | $1.55M | Buy |
144,755
+13,305
| +10% | +$145K | ﹤0.01% | 2205 |
|
|
2015
Q2 | $1.06M | Buy |
131,450
+3,793
| +3% | +$27.9K | ﹤0.01% | 2393 |
|
|
2015
Q1 | $844K | Buy |
127,657
+6,219
| +5% | +$42.5K | ﹤0.01% | 2442 |
|
|
2014
Q4 | $774K | Buy |
121,438
+36,345
| +43% | +$293K | ﹤0.01% | 2459 |
|
|
2014
Q3 | $840K | Sell |
85,093
-8,681
| -9% | -$92.7K | ﹤0.01% | 2381 |
|
|
2014
Q2 | $1.06M | Sell |
93,774
-8,226
| -8% | -$88.4K | ﹤0.01% | 2287 |
|
|
2014
Q1 | $1.24M | Buy |
102,000
+2,701
| +3% | +$34.5K | ﹤0.01% | 2177 |
|
|
2013
Q4 | $1.25M | Buy |
99,299
+12,009
| +14% | +$191K | ﹤0.01% | 2163 |
|
|
2013
Q3 | $1.77M | Sell |
87,290
-33,819
| -28% | -$567K | ﹤0.01% | 1922 |
|
|
2013
Q2 | $1.94M | Buy |
+121,109
| New | +$1.84M | ﹤0.01% | 1775 |
|
Other funds holding LXRX
AG
SL
SC
Charles Schwab's LXRX Position: Q2 2026 in Review
Charles Schwab increased its Lexicon Pharmaceuticals (LXRX) stake by 49% in Q2 2026, buying an estimated $1.26M and bringing the position to 1,956,775 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2513.
Charles Schwab first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.7M in Q3 2016. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.
- Charles Schwab held 1,956,775 shares of Lexicon Pharmaceuticals worth $4.7M as of Q2 2026.
- Charles Schwab bought 645,477 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $1.26M.
- Lexicon Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2513 holding.
- Charles Schwab first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Lexicon Pharmaceuticals position peaked at $5.7M in Q3 2016.
- 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.